4.6 Article

Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer

Journal

JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 118, Issue 10, Pages 3391-3400

Publisher

WILEY
DOI: 10.1002/jcb.25995

Keywords

microRNA-155; PTPRJ; COLORECTAL CANCER

Funding

  1. Fundamental Research Funds for the Central Universities [WUT: 2015IB004, WUT: 2017IVA112, WUT: 2017IB004]
  2. China Postdoctoral Science Foundation [2015M582291]

Ask authors/readers for more resources

PTPRJ is known for its antiproliferative role. Loss of heterozygosity (LOH) of PTPRJ has frequently been observed in various human cancers including colorectal cancer (CRC), lung cancer, and breast cancer. However, the function and mechanism of PTPRJ in CRC are not well understood. At the present study, we show that ectopic expression of PTPRJ inhibits cell growth, migration, and invasiveness in CRC cell line HCT116. Moreover, PTPRJ inhibits the tumorigenecity of HCT116 in a xenograft tumor model. MiR-155, the well-known oncomiR in CRC, is identified as an upstream factor of PTPRJ. MiR-155 directly binds to the 3 untranslated region of PTPRJ mRNA and suppresses the mRNA and protein levels of PTPRJ. Furthermore, the growth-promoting and AKT signaling activation effect of miR-155 was abrogated by PTPRJ overexpression, and vice versa. Our study reveals the crucial role of miR-155/PTPRJ/AKT axis in proliferation and migration of CRC cells and suggests a therapeutic potential of PTPRJ. (C) 2017 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available